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Abstract
BACKGROUND: The aim of the present study was to estimate the impact of inherited thrombophilia
(IT) on the risk of venous thromboembolism (VTE) onset and recurrence in children by a meta-analysis
of published observational studies. METHODS AND RESULTS: A systematic search of electronic
databases (Medline, EMBASE, OVID, Web of Science, The Cochrane Library) for studies published
from 1970 to 2007 was conducted using key words in combination as both MeSH terms and text words.
Citations were independently screened by 2 authors, and those meeting the inclusion criteria defined a
priori were retained. Data on year of publication, study design, country of origin, number of
patients/controls, ethnicity, VTE type, and frequency of recurrence were abstracted. Heterogeneity
across studies was evaluated, and summary odds ratios and 95% CIs were calculated with both
fixed-effects and random-effects models. Thirty-five of 50 studies met inclusion criteria. No significant
heterogeneity was discerned across studies. Although >70% of patients had at least 1 clinical risk factor
for VTE, a statistically significant association with VTE onset was demonstrated for each IT trait
evaluated (and for combined IT traits), with summary odds ratios ranging from 2.63 (95% CI, 1.61 to
4.29) for the factor II variant to 9.44 (95% CI, 3.34 to 26.66) for antithrombin deficiency. Furthermore,
a significant association with recurrent VTE was found for all IT traits except the factor V variant and
elevated lipoprotein(a). CONCLUSIONS: The present meta-analysis indicates that detection of IT is
clinically meaningful in children with, or at risk for, VTE and underscores the importance of pediatric
thrombophilia screening programs.
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Impact of Inherited Thrombophilia on Venous
Thromboembolism in Children
A Systematic Review and Meta-Analysis of Observational Studies
Guy Young, MD; Manuela Albisetti, MD; Mariana Bonduel, MD; Leonardo Brandao, MD;
Anthony Chan, MD; Frauke Friedrichs, PhD; Neil A. Goldenberg, MD; Eric Grabowski, MD;
Christine Heller, MD; Janna Journeycake, MD; Gili Kenet, MD; Anne Krümpel, MD;
Karin Kurnik, MD; Aaron Lubetsky, MD; Christoph Male, MD; Marilyn Manco-Johnson, MD;
Prasad Mathew, MD; Paul Monagle, MD; Heleen van Ommen, MD; Paolo Simioni, MD;
Pavel Svirin, MD; Daniela Tormene, MD; Ulrike Nowak-Göttl, MD
Background—The aim of the present study was to estimate the impact of inherited thrombophilia (IT) on the risk of venous
thromboembolism (VTE) onset and recurrence in children by a meta-analysis of published observational studies.
Methods and Results—A systematic search of electronic databases (Medline, EMBASE, OVID, Web of Science, The
Cochrane Library) for studies published from 1970 to 2007 was conducted using key words in combination as both
MeSH terms and text words. Citations were independently screened by 2 authors, and those meeting the inclusion
criteria defined a priori were retained. Data on year of publication, study design, country of origin, number of
patients/controls, ethnicity, VTE type, and frequency of recurrence were abstracted. Heterogeneity across studies was
evaluated, and summary odds ratios and 95% CIs were calculated with both fixed-effects and random-effects models.
Thirty-five of 50 studies met inclusion criteria. No significant heterogeneity was discerned across studies. Although
70% of patients had at least 1 clinical risk factor for VTE, a statistically significant association with VTE onset was
demonstrated for each IT trait evaluated (and for combined IT traits), with summary odds ratios ranging from 2.63 (95%
CI, 1.61 to 4.29) for the factor II variant to 9.44 (95% CI, 3.34 to 26.66) for antithrombin deficiency. Furthermore, a
significant association with recurrent VTE was found for all IT traits except the factor V variant and elevated
lipoprotein(a).
Conclusions—The present meta-analysis indicates that detection of IT is clinically meaningful in children with, or at risk for,
VTE and underscores the importance of pediatric thrombophilia screening programs. (Circulation. 2008;118:000-000.)
Key Words: meta-analysis  pediatrics  recurrence  thrombosis
Venous thromboembolism (VTE) in children is a raredisease that is being increasingly diagnosed and recog-
nized, usually as a secondary complication of primary under-
lying medical diseases such as sepsis, cancer, and congenital
heart disease, as well as therapeutic interventions such as the
use of central venous lines.1–6 Pediatric VTE is a severe
condition for which long-term outcomes have included lack
of thrombus resolution in 50% of cases and, excluding central
line–associated thrombosis in children with malignancy, the
development of postthrombotic syndrome in more than one
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third of patients.7–11 Within the entire childhood population,
neonates are at the greatest risk of thromboembolism (5.1/
100 000 live births per year in white children), with a second
peak in incidence during puberty and adolescence.2 In pro-
spective pediatric registries in North America and Europe, the
annual incidence of venous events was estimated to be 0.7 to
1.4 per 100 000 children or 5.3 per 10 000 hospital admis-
sions of children and 24 per 10 000 admissions of neonates to
neonatal intensive care units.6,12–14
Clinical Perspective p ●●●
The results of single studies of the risk of VTE onset and
recurrence associated with inherited thrombophilia (IT) have
been contradictory or inconclusive, mainly because of a lack
of statistical power. Apart from acquired thrombophilic risk
factors such as the presence of antiphospholipid antibod-
ies,15–18 IT—particularly antithrombin, protein C, and protein
S deficiency, variants of coagulation factor V (G1691A) and
factor II (G20210A), and elevated lipoprotein(a)–have been
established as risk factors for venous thromboembolic events
in adults.19–29 The allele frequencies for the factor V G1691A
or factor II G20210A variants differ among various ethnic
groups.30–32 In children with idiopathic VTE and in pediatric
populations in which thromboses were associated with un-
derlying medical diseases, IT has been described as an
additional prothrombotic risk factor.33–101 Follow-up data for
VTE recurrence in children are available from several re-
ports12,13,17,62,63,67,69,78–81,93,100 and suggest a recurrence rate
of 3% in neonates and 8% in older children. Unfortunately,
the duration of follow-up is variable across studies. However,
in the pediatric age group, it is unknown whether thrombus
recurrence and other thrombotic outcomes in children are
affected by IT; thus, it remains controversial whether children
with thrombosis or offspring in thrombosis-prone families
benefit from screening for IT.102–108 The aim of this system-
atic review and meta-analysis was to determine the impact of
IT on VTE onset and recurrence in children as a prerequisite
to the evaluation of primary and secondary treatment options
through randomized controlled trials.
Methods
The present systematic review and meta-analysis was performed in
accordance with the recently published guidelines from Strengthen-
ing the Reporting of Observational Studies in Epidemiology
(STROBE),109 with adaptations as further described below.
Inclusion/Exclusion Criteria
Published studies of VTE in children 20 years of age from 1970
through August 2007 were evaluated for inclusion if the frequency of
1 IT traits was individually investigated in a given VTE cohort
(descriptive analysis) and if the frequency of IT traits was compared
between VTE patients and control subjects without a history of VTE
in a given study (meta-analysis). Pediatric VTEs of any location
objectively confirmed by suitable imaging methods were included.
In addition, to be included, publications must have reported the
country of origin, study design, ethnicity, number of patients and
controls, type of VTE, number of individuals tested for IT, screening
tests performed, and laboratory methods (including criteria for
normal/abnormal results). In addition, in children with recurrent
events, data on the time to recurrence, VTE type and location of
recurrence, associated clinical risk factors, and duration and type of
anticoagulation110 were required. Case reports and case series/studies
in which 50% of cases were systematically screened for IT,
publications reporting asymptomatic thrombosis, and studies with
unclear laboratory/analytical methodology to differentiate between
inherited and acquired deficiency states of protein C, protein S, or
antithrombin were not included (except in instances when this
distinction was subsequently clarified in personal communication
with the responsible authors; only cases with inherited deficiency
states were included in the analyses).
Search Strategy
A systematic search of publications listed in the electronic databases
(Medline via PubMed, EMBASE, OVID, Web of Science, The
Cochrane Library) from 1970 to August 2007 was conducted using
the following key words in combination as both MeSH terms and
text words: [“deep vein thrombosis” or “thromboembolism” or
“venous thromboembolism” or “pulmonary embolism” or “renal
venous thrombosis” or “cerebral venous thrombosis” or “anticoagu-
lation” OR “antithrombotic therapy”] and [“neonate” or “infant” or
“children” or “child” or “childhood” or “adolescents” or “pediatric”
or “pediatric” not “adult”] and [“thrombophilia” or “prothrombotic”
or “procoagulant” or “protein C” or “protein S“ or “antithrombin” or
“factor V” or “activated protein C resistance” or “prothrombin“ or
”factor II” or “lipoprotein (a)”]. The terms “catheter-related,”
“central-line-related,” and “recurrence” or “recurrent” also were
included in the search strategy. In addition, reference lists of journal
articles identified through the aforementioned search were searched
manually to locate additional studies. The search strategy had no
language restrictions. Citations were screened and classified into
cohort/case-control, case series, or registry data by 2 independent
group members (L.B. and H.v.O.). Those meeting the inclusion
criteria were retained. The decision to include or exclude studies
was hierarchical, made initially on the basis of the study title,
followed by the abstract, and finally the complete body text. In
the event of conflicting opinions, resolution was achieved though
discussion (L.B., F.F., N.G., J.J., G.K., A.K., M.M.-J., U.N.G.,
H.v.O., and P.S.).
Data Extraction
To avoid possible double counting of patients included in 1 report
by the same authors/working groups, the patient recruitment periods
and catchment areas were evaluated, and authors were contacted for
clarification. If the required data could not be located in the
published report, the corresponding author was asked to provide the
missing data of interest. Data extractions were checked for accuracy
by multiple reviewers (M.A., L.B., F.F., J.J., G.K., M.M.-J., H.v.O.,
P.S., and G.Y.).
Study Design Classification
In this meta-analysis, studies were classified as having a cohort
design when subjects with and without a factor being investigated
were followed up for development of the outcome of interest. Studies
were classified as having a case-control design when individuals
grouped by outcome (ie, cases having the outcome/disease of interest
and controls without the outcome/disease) were compared for the
presence of a risk factor of interest. A case report or case series was
defined as 1 case or a group of cases of a particular outcome of
interest with no control group. Studies were classified as having a
registry design when consisting of a multicenter population-based
(ascertainment of 90% of cases available) case series using
predefined standardized data collection criteria.111
Missing Data
Studies in which symptomatic pediatric VTE patients were not
screened for ITs and studies in which the thrombophilia screening
was done in50% of cases or was performed only sporadically were
not included in the present meta-analysis. When the percentage of
patients screened for IT was not clear from the article, authors were
asked for clarification.
2 Circulation September 23, 2008
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Statistical Analyses
Data analyses were performed with STATA version 9 update and
StatsDirect version 2.6.6 update (Altrincham, Trafford, UK: WWW.
STATSDIRECT.COM). Continuous data are presented as median
(minimum and maximum) values. For meta-analysis, summary odds
ratios (ORs) and 95% CIs were calculated from the effect estimates
of the individual studies weighted by SE using both a fixed-effects
model (weighting each estimate by its SE via the Mantel-Haenszel
method) and a random-effects model (estimating between-study
variance in effect measures according to DerSimonian and Laird);112
the latter approach was used to control for heterogeneity according to
Higgins et al.113 For both the factor V and factor II variants, the AA
and GA alleles (ie, homozygosity and heterozygosity for A alleles)
were analyzed together and compared with the absence of these
genotypes as the reference category. A value of P0.05 was
considered statistically significant. In addition, we assessed hetero-
geneity among studies using I2 statistics. When P0.05, the presence
of heterogeneity was considered statistically significant, and when
I250%, the magnitude of heterogeneity was considered substantial.
Funnel plots of effect size against SE and a modified linear
regression test were used to describe the presence of publication
bias.114 In study design classification, the degree of agreement
beyond chance between first and second raters was measured by 
statistic.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Descriptive Analyses
From 331 potentially relevant citations ascertained from
electronic databases and search of reference lists, 50 cohort/
case-control studies or case series/registries from 16 countries
finally met the inclusion criteria for descriptive analysis
(Figure 1 and Tables Ia, Ib, and II of the online Data
Supplement). Apart from Reference 63, which reported the
follow-up of high-risk children with idiopathic VTE, in these
studies, 70% of patients with VTE had at least 1 clinical
risk factor. In neonates and infants, these risk factors were
predominantly medical diseases such as systemic sepsis,
dehydration, congenital heart disease, or short-term central
venous lines; in older children and adolescents, cancer and
polychemotherapy, immobilization after surgery or plaster
casts, obesity, rheumatic diseases, local infections, and the
use of oral contraceptives pills (adolescent girls) were the
leading exogenous triggers. Measurement of interrater reli-
ability in study design classification showed a substantial
agreement (92.68%) beyond that expected by chance alone
(22.78%) in the analysis of VTE onset (0.90; Z11.08;
P0.001), and in the analysis of VTE recurrence, the
agreement beyond chance (24.8%) was 81.82% (0.76;
Z4.91; P0.001).
Studies investigating IT at the onset of VTE are shown in
the supplemental tables. Forty-one of the 50 studies reported
inherited deficiency states of protein C, protein S, or anti-
thrombin. In these studies, 2653 patients with a first VTE
onset and 1979 control children were investigated (supple-
mental Table Ia). Beginning in 1996 and 1999, the factor V
and factor II variants, respectively, were systematically in-
vestigated in childhood VTE (44 studies; supplemental Table
potentially relevant papers identified
from electronic databases
n=319
additionally  identified
papers from citations/references
n=10
papers found after main search
n=2
total papers retrieved from 
search & reference lists for 
detailed evaluation
n=331
excluded: n=281
reasons for exclusion
•reviews = 50
•IT not investigated = 105
•therapeutic aspects = 27
•ischemic stroke = 17
•case reports = 72
•duplicate publications = 10
qualifying studies (descriptive):  n=50
case series: no controls = 15
cohort = 29
case-control = 6
qualifying studies (meta-analysis):  n=35
cohort = 29
case-control = 6
Figure 1. Flow chart showing results of the search
strategy and reasons for exclusion.
Young et al Thrombophilia and Childhood Venous Thromboembolism 3
 at Universitaet Zuerich on February 25, 2009 circ.ahajournals.orgDownloaded from 
Ib). For the rare event of VTE recurrence, patients derived
from 6 to 13 studies met the inclusion criteria. The median
follow-up time was 48 months (minimum, 12 months; max-
imum, 96 months). The median age at onset in studies
reporting recurrent VTE was 7.2 years (minimum, 0.1 years;
maximum, 14.0 years) with a median age at recurrence of 14
years (minimum, 3.6 years; maximum, 15.0 years). Data on
anticoagulation at the time of recurrence were available for
127 children from 7 reports. In 25 of 127 patients (19.7%),
recurrence presented during anticoagulation therapy, and in
the majority of cases, ie, in 102 of the 127 patients (80.3%),
the second VTE occurred after withdrawal of anticoagulation.
Study characteristics and the rates of recurrent VTE are shown in
supplemental Table II. The proportion of children developing
recurrent VTE over the median follow-up period was 11.4%.
Of note, because of authors’ clarifications, individual
numbers of patients and controls in the studies listed in
supplemental Table I and Tables 1 and 2 may vary from the
original study articles. In addition, subject numbers for the
analyses differ in Table 2 and supplemental Table II relative
to the prior tables because of the reliance on case-control
studies in the estimation of risk of first VTE onset.
Table 1. Summary ORs (95% CIs; Meta-Analysis) Including Testing for Heterogeneity (I2) and Publication Bias for Genetic Traits
Associated With a First VTE Onset in Children
Genetic Traits (No. of Studies) Patients/Controls, n OR (95% CI), Fixed Model OR (95% CI), Random Model I2, % Bias Indicator114
Protein C deficiency (16) 1079/1979 7.72 (4.440–13.42) 7.75 (4.48–13.38) 0
P 0.0001 0.0001 0.75 0.13
Protein S deficiency (16) 1075/1979 5.77 (3.03–10.97) 5.77 (3.07–10.85) 0
P 0.0001 0.0001 0.92 0.30
Antithrombin deficiency (16) 1072/1979 9.44 (3.34–26.66) 8.73 (3.12–24.42) 0.0
P 0.0001 P0.0001 0.96 0.27
Factor V G1691A (23) 1430/2623 3.77 (2.98–4.77) 3.56 (2.57–4.93) 33.4
P 0.0001 0.0001 0.08 0.78
Factor II G20210A (14) 916/1673 2.64 (1.60–4.41) 2.63 (1.61–4.29) 0
P 0.0001 0.0001 0.90 0.71
Lipoprotein(a) (8) 589/1441 4.49 (3.26–6.18) 4.50 (3.19–6.35) 8.3
P 0.0001 0.001 0.36 0.14
2 Genetic traits (12) 965/1625 9.5 (4.92–18.39) 8.89 (3.43–23.06) 38.3
P 0.0001 0.0001 0.11 0.57
Table 2. Summary ORs (95% CIs; Meta-Analysis) Including Testing for Heterogeneity (I2) and Publication Bias for Genetic Traits
Associated With Recurrent VTE in Children
Genetic Traits (No. of Studies)
Patients With
Recurrence/Patients
With No
Recurrence, n OR (95% CI), Fixed Model OR (95% CI), Random Model I2, % Bias Indicator114
Protein C deficiency (13) 152/1296 2.39 (1.21–4.36) 2.53 (1.30–4.92) 0
P 0.012 0.006 0.74 0.67
Protein S deficiency (11) 132/857 3.12 (1.50–6.45) 3.76 (1.76–8.04) 0
P 0.001 0.0006 0.51 0.41
Antithrombin deficiency (12) 150/969 3.01 (1.43–6.33) 3.37 (1.57–7.20) 0
P 0.003 0.001 0.74 0.59
Factor V G1691A (12) 115/1160 0.64 (0.35–1.18) 0.77 (0.40–1.45) 0
P 0.18 0.42 0.68 0.48
Factor V G1691A including children
with idiopathic/spontaneous VTE
only (13)
179/1397 1.35 (0.91–1.98) 1.43 (0.91–2.24) 4.3
P 0.107 0.114 0.40 0.004
Factor II G20210A (12) 171/1397 1.88 (1.01–3.49) 2.15 (1.12–410) 0
P 0.049 0.020 0.66 0.52
Lipoprotein(a) (6) 135/1020 0.81 (0.49–1.36) 0.84 (0.50–1.40) 0
P 0.51 0.50 0.90 0.78
2 Genetic traits (10) 144/1127 4.46 (2.89–6.89) 4.91 (3.12–7.74) 0.7
P 0.0001 0.0001 0.43 0.82
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Meta-Analyses
In 35 of 50 studies, eligible data on VTE children and
population-based controls were reported. For the event of
VTE onset, patients derived from 8 to 23 studies were
available. Table 2 summarizes the genetic traits investigated,
the number of studies and patients included in the meta-anal-
ysis, and summary ORs and 95% CIs under a fixed-effects
and random-effects model. In addition, results of testing for
heterogeneity and publication bias are shown. No significant
heterogeneity or publication bias was discerned across stud-
ies. ORs were first calculated separately by age groups
(neonate, infant, child, adolescent). Because no statistically
significant difference in ORs was detected with age (data not
shown), summary ORs were then calculated for the overall
pediatric age range. A statistically significant association with
VTE onset was demonstrated for each IT trait evaluated (and
for combined IT traits), with summary ORs ranging from
2.63 (95% CI, 1.61 to 4.29) for the factor II variant to 9.44
(95% CI, 3.34 to 26.66) for antithrombin deficiency. Forest
plots under random-effects models show that pediatric carri-
ers of the factor II variant (Figure 2A) and of2 genetic traits
(Figure 2b) had an increased risk of developing a first
symptomatic VTE. Furthermore, a significant association
with recurrent VTE was found for all IT traits except the
factor V variant and elevated lipoprotein(a), with summary
ORs ranging from 1.88 (95% CI, 1.01 to 3.49) for the factor
II variant to 3.76 (95% CI, 1.76 to 8.04) for protein S
deficiency. Substantial heterogeneity across studies was ruled
out. When analyzing the role of factor V G1691A and
recurrence, we achieved higher homogeneity and the absence
of major publication bias after exclusion of Reference 63,
which reported solely the follow-up of selected high-risk
pediatric patients with idiopathic VTE (Table 2). Again,
funnel plots of effect size against SE were explored for each
parameter investigated and were broadly symmetrical, which
was consistent with the conclusion that there was no major
publication bias (data of bias assessment plots are exemplar-
ily shown for the factor II mutation [supplemental Figure
IIIa] and combined genetic traits at recurrent VTE [supple-
mental Figure IIIb]). The absence of major publication bias
was also underlined by the results of the linear regression
method according to Harbord et al.114
Discussion
VTE is far less common in children than in adults and often
is associated with underlying medical conditions such as
malignancy, autoimmune disease, and congenital heart dis-
ease or is caused by medical interventions such as central
venous lines. Keeping in mind that not all children with these
risk factors will develop VTE, it is apparent that genetic risk
factors play an important role in which children will develop
thrombosis.33–101,115,116 Apart from a recent systematic review
of the role of thrombophilia in children with acute lympho-
blastic leukemia and ischemic stroke,117,118 to the best of our
knowledge, this is the first meta-analysis of observational
studies investigating the association of genetic traits and VTE
in children. Each of the traits investigated shows a significant
association with first onset of pediatric VTE, with the highest
ORs found for combined genetic traits and deficiencies of
antithrombin, protein C, and protein S. Our findings are
concordant with adult studies demonstrating that inherited
deficiencies of the natural anticoagulants protein C, protein S,
and antithrombin are present in 10% of patients with VTE
but that patients with these deficiency states are considered at
higher risk for a first VTE onset.119 In the white adult
population, the factor V mutation increases the risk of a first
episode of VTE by 3- to 7-fold, whereas the factor II variant
increases the risk by 2- to 3-fold.120,121 In addition, it has been
demonstrated in a recent meta-analysis that elevated lipopro-
tein(a) increases the risk of a first symptomatic VTE in adults
nearly 2-fold.29
A history of thrombosis is a predictor for VTE recurrence
in adults in 3% to 13% of consecutive patients after 1 year
and in 12% to 28% after 5 years.119 In pediatric cohorts, the
proportion of children developing recurrent VTE ranged from
3% in neonates to 8% in older children2,12–14 and as high as
21% in children reported with a first idiopathic VTE.63 The
results of this meta-analysis show that 11.4% of children with
nonidiopathic thrombosis overall (ie, regardless of IT status)
developed a second VTE, which is consistent with the rate
reported in large pediatric cohort studies not systematically
investigating genetic traits.2,12,14,79 Second events, however,
were observed mainly in adolescents and occurred in 80%
of affected children after withdrawal of anticoagulant ther-
apy. In the present meta-analysis, a significant association
with recurrent VTE in children was found for protein C,
protein S, and antithrombin deficiency; the factor II variant;
and 2 genetic traits. Pediatric carriers of the factor V
mutation or elevated lipoprotein(a) did not show an increased
risk for recurrent VTE in the present analysis. The summary
ORs determined in this meta-analysis for recurrent VTE in
children are consistent with results obtained from adult
cohort studies of patients not receiving long-term
anticoagulation.119,122–124
The present meta-analysis has several limitations. First, the
included studies were conducted over different time periods;
therefore, it has to be taken into consideration that diagnosis
and treatment modalities, including referral patterns, might
have changed over time. Second, most of the studies included
in our meta-analysis were undertaken in white children with
VTE; thus, it is unknown whether our findings can be
extrapolated to other ethnic groups. A third limitation is the
possible presence of publication bias. Although formal testing
did not show a publication bias, it cannot be completely ruled
out, considering the rarity of the disease and the small number
of studies available in the field of pediatric VTE. It should
also be mentioned here that the pediatric age groups most
affected, ie, newborns and adolescents, are underrepresented
in the present analysis. The former may be due to the fact that
apart from genetic testing, thrombophilia screening and its
interpretation are difficult in small children and may therefore
be postponed by the treating physicians, with the increasing
risk of patients lost to follow-up. As a consequence, data
obtained from this meta-analysis have to be interpreted with
caution, especially for infants within the first year of life. A
fourth limitation of the study, specifically with regard to the
VTE recurrence analysis, is that data were not available for
the duration of follow-up on a per-patient level, so recurrence
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Factor II G20210A at first VTE onset:
Odds ratio meta-analysis plot [random effects]
0,01 0,1 0,2 0,5 1 2 5 10 100 1000
Komitopulu 2006 5,13 (0,80, 36,61)
Pinto 2004 6,33 (0,05, infinity)
Özyurek 2007 2,50 (0,40, 26,69)
Nowak-Göttl 1999b 1,63 (0,03, 15,19)
Kosch 2004 5,37 (0,84, 57,49)
Knöfler 1999 6,90 (0,10, 148,12)
Kenet 2004 0,73 (0,01, 7,70)
Junker 1999 3,21 (1,01, 11,92)
Heller 2003 2,40 (0,53, 14,62)
Heller 2000 0,96 (0,00, 114,71)
El-Karaksky 2004 7,72 (0,62, infinity)
Bonduel 2002 1,16 (0,18, 6,09)
Albisetti 2007 0,36 (0,00, 5,25)
combined [random] 2,58 (1,56, 4,25)
odds ratio (95% confidence interval)
> two defects at first VTE onset:
Odds ratio meta-analysis plot [random effects]
0,01 0,1 0,2 0,5 1 2 5 10 100 1000
Kosch 2004 56,20 (5,81, infinity)
Kenet 2004 1,19 (0,11, 7,65)
Gurgey 2004 1,81 (0,06, infinity)
Heller 2003 24,44 (2,17, infinity)
Bonduel 2002 13,84 (0,80, infinity)
Nowak-Göttl 1999b 42,50 (7,66, 419,96)
Nowak-Göttl 1999a 7,49 (1,67, 68,55)
Junker 1999 10,17 (1,29, 459,53)
Sifontes 1998 2,73 (0,02, infinity)
combined [random] 8,89 (3,43, 23,06)
odds ratio (95% confidence interval)
A
B
Figure 2. A, The Forest plot shows ORs and 95% CIs for observational studies investigating the influence of the factor II G20210A mutation on the
onset of symptomatic venous thromboembolism in children. The study author and year of publication are indicated on the y axis. The box for each
study is proportional to the inverse of variance; horizontal lines show the 95% CIs of the ORs. The pooled estimate is based on a random-effects
model shown by a vertical line and diamond (95% CI). Studies are in descending order by year of publication. Studies with patients/controls
counted as “zero” are not depicted (Reference 94). B, The Forest plot shows ORs and 95% CIs for observational studies investigating the influence
of 2 genetic traits on the onset of symptomatic venous thromboembolism in children. The study author and year of publication are indicated on
the y axis. The box for each study is proportional to the inverse of variance; horizontal lines show the 95% CIs of the ORs. The pooled estimate is
based on a random-effects model shown by a vertical line and diamond (95% CI). Studies are in descending order by year of publication. Studies
with patients/controls counted as “zero” are not depicted (References 48 and 59).
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risk may be biased by differences in duration of follow-up
across studies.
These limitations notwithstanding, the finding of the pres-
ent meta-analysis that IT is associated with VTE onset and its
recurrence in children has important implications for future
advances in the field. Decisions on extending anticoagulation
therapy are individually based on the perceived risks of VTE
recurrence and anticoagulation-related bleeding, and whether
long-term continuation of anticoagulation treatment should
be considered after a first VTE in carriers of a thrombophilic
trait is still a matter of debate. Randomized controlled trials
are lacking in children with a first VTE, and treatment
guidelines are mainly adapted from adults.110,125 More than in
the typical elderly adult with VTE, the prolonged use of
anticoagulation treatment in a physically active pediatric
group must be weighed against the risk of bleeding. The
results of this meta-analysis suggest that future investigation
of secondary prevention in pediatric VTE should include
trials of prolonged anticoagulation treatment duration tar-
geting high-risk IT groups, particularly children with VTE
who have combined IT but do not presently meet the
criteria (eg, severe anticoagulant deficiency) for indefinite
anticoagulation.
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CLINICAL PERSPECTIVE
The role of inherited thrombophilia in the onset and recurrence of pediatric venous thromboembolism (VTE) is unclear.
Previous publications reporting the occurrence of inherited thrombophilia in pediatric patients with VTE consist largely of
case reports and case series. Although there are a number of prospective and retrospective controlled studies, they generally
suffer from methodological problems (often sample sizes that are too small) that preclude any from being definitive. As
a result, physicians caring for children with VTE cannot appropriately decide on the utility of thrombophilia testing, leading
some physicians to evaluate all such patients and others to perform no testing. Thus, we performed a meta-analysis to
provide more definitive answers that can provide some guidance on this controversial issue. The results of this
meta-analysis demonstrate that all thrombophilia traits included in the study are associated with the onset of VTE and most
are associated with recurrence [except factor V Leiden and lipoprotein(a)]. These results suggest that thrombophilia testing
based on the individual genetic background of the patient may be important in the management of children with VTE.
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